In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ArQule acquires Camitro

Executive Summary

ArQule acquired predictive modeling company Camitro Corp. for $76.3mm. According to ArQule's most recent 8-K filing, it paid with 3.4mm ArQule common shares at $24.13 each (the trading price just before the deal closed) and $1.73mm in cash. Camitro will continue operations under its own name, as a wholly owned ArQule subsidiary.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies